STUDY ON TREATMENT OF THE LEACHATE FROM LANDFILL SITE AT NAMSON, SOCSON, HANOI

Joint Research on Environmental Science and Technology for the Eart

Summary of study design and enrollment.

<p>Summary of study design and enrollment.</p

Characteristics of index cases.

<p>Characteristics of index cases.</p

Spatial and temporal distribution of cluster investigations.

<p>A: Map of Ho Chi Minh City, with inset showing the spatial distribution of dengue positive clusters (filled circles) and negative clusters (open diamonds) within 7 central districts (district numbers are shown). B: Number of dengue positive and negative cluster investigations, by month of enrollment.</p

Cluster composition and characteristics of cluster participants.

<p>*Denominator for percentages is the number of participants with an enrollment sample collected at Visit 1.</p><p>Cluster composition and characteristics of cluster participants.</p

Multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization

Despite their promise, circulating tumor DNA (ctDNA)-based assays for multi-cancer early detection face challenges in test performance, due mostly to the limited abundance of ctDNA and its inherent variability. To address these challenges, published assays to date demanded a very high-depth sequencing, resulting in an elevated price of test. Herein, we developed a multimodal assay called SPOT-MAS (screening for the presence of tumor by methylation and size) to simultaneously profile methylomics, fragmentomics, copy number, and end motifs in a single workflow using targeted and shallow genome-wide sequencing (~0.55×) of cell-free DNA. We applied SPOT-MAS to 738 non-metastatic patients with breast, colorectal, gastric, lung, and liver cancer, and 1550 healthy controls. We then employed machine learning to extract multiple cancer and tissue-specific signatures for detecting and locating cancer. SPOT-MAS successfully detected the five cancer types with a sensitivity of 72.4% at 97.0% specificity. The sensitivities for detecting early-stage cancers were 73.9% and 62.3% for stages I and II, respectively, increasing to 88.3% for non-metastatic stage IIIA. For tumor-of-origin, our assay achieved an accuracy of 0.7. Our study demonstrates comparable performance to other ctDNA-based assays while requiring significantly lower sequencing depth, making it economically feasible for population-wide screening